Amantadine Hydrochloride

  • # LGM Pharma is a Amantadine Hydrochloride CAS# 665-66-7 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, samples, sourcing, purity and more.
  • # Questions? Call our customer API support number 1-(800)-881-8210.
  • # LGM Pharma offers this active ingredient but not the finished dosage forms.
  • Inquire about this product >>

Product Details:

  • Product Name: Amantadine Hydrochloride
  • CAS #: 665-66-7
  • Mode of Action:

    The mechanism of its antiparkinsonic effect is not fully understood, but it appears to be releasing dopamine from the nerve endings of the brain cells, together with stimulation of norepinephrine response. It also has NMDA receptor antagonistic effects. The antiviral mechanism seems to be unrelated. The drug interferes with a viral protein, M2 (an ion channel), which is needed for the viral particle to become "uncoated" once it is taken inside the cell by endocytosis.

  • Pharmacodynamics:

    Amantadine is an antiviral drug which also acts as an antiparkinson agent, for which it is usually combined with L-DOPA when L-DOPA responses decline (probably due to tolerance). It is a derivate of adamantane, like a similar drug rimantadine. The mechanism of action of amantadine in the treatment of Parkinson's disease and drug-induced extrapyramidal reactions is not known. It has been shown to cause an increase in dopamine release in the animal brain, and does not possess anticholinergic activity.

  • Metabolism:

    No appreciable metabolism, although negligible amounts of an acetyl metabolite have been identified.

  • Toxicity:

    Deaths have been reported from overdose with amantadine. The lowest reported acute lethal dose was 2 grams. Drug overdose has resulted in cardiac, respiratory, renal or central nervous system toxicity. Cardiac dysfunction includes arrhythmia, tachycardia and hypertension. Pulmonary edema and respiratory distress (including ARDS) have been reported. Renal dysfunction including increased BUN, decreased creatinine clearance and renal insufficiency can occur. Central nervous system effects that have been reported include insomnia, anxiety, aggressive behavior, hypertonia, hyperkinesia, tremor, confusion, disorientation, depersonalization, fear, delirium, hallucination, psychotic reactions, lethargy, somnolence and coma. Seizures may be exacerbated in patients with prior history of seizure disorders. Hyperthermia has also been observed in cases where a drug overdose has occurred.

  • IUPAC: 1-Adamantanamine, hydrochloride Amantadine hydrochloride Tricyclo( 3, 7))decan-1-amine, hydrochloride (9CI) Tricyclo(, 7)decan-1-amine, hydrochloride Tricyclo(, 7)decan-1-amine, hydrochloride (1:1)
  • ATC: N04BB01
  • DrugBank: DB00915
  • Formula: C10-H17-N.Cl-H
  • Molecular Mass: 187.712
  • Synonyms: 1-Adamantanamine hydrochloride, 1-Adamantylamine hydrochloride, 1-Aminoadamantane hydrochloride, 1-Aminoadamantene hydrochloride, Adamantanamine hydrochloride, Adamantine hydrochloride, Adamantylamine hydrochloride, AI3-52211, Amantadine HCl, Amantadine hydrochloride, Amantan, Amazolon, Aminoadamantane hydrochloride, EC 211-560-2, EINECS 211-560-2, EXP 105-1, EXP-105-1, GP 38026, Influenol, Midantan, Midantane, Mydantane, NSC 83653, Symadine, Symmetrel, Trivaline, UNII-M6Q1EO9TD0, Virasol, Viregyt, Virofral, Virosol
  • SMILES: Cl.C1C2CC3CC1CC(C3)(C2)N
  • AHFS Code: 08:18.0
  • InChl: 1S/C10H17N.ClH/c11-10-4-7-1-8(5-10)3-9(2-7)6-10;/h7-9H,1-6,11H2;1H
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

API’s From Quality Manufacturers:

  • Streamlined API supply towards initial research stages as well as larger quantities of cGMP material for clinical trials and product commercialization
  • Premium quality GMP certified and fully accredited API manufacturing plants


  • Technical packages as well as access to filed DMF,
    ASMF or CEP (subject to availability)
  • Regulatory and technical assistance towards any
    submission type based on specific customer requirements

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service